Effectiveness of Trastuzumab Deruxtecan in Adults with HER2-positive Advanced Solid Tumors Without Other Treatment Options

What this Trial Is About

Researchers are evaluating the effectiveness of trastuzumab deruxtecan T-DXd in patients with HER2-positive IHC 3 locally advanced, unresectable, or metastatic solid tumors in the United States. This observational study focuses on patients who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options. The study excludes patients with breast, colorectal, non-small cell lung cancer, gastricgastroesophageal junction cancers, and hematological malignancies. Participants will be enrolled at approximately 30 sites including community oncology practices, hospital systems, and academic medical centers. They will start treatment with T-DXd as part of routine clinical care according to the FDA label. The study is designed to reflect real-world clinical practice and will observe patients from the point they begin T-DXd treatment. During the study, researchers will collect data on tumor response and treatment outcomes over up to 2.5 years after enrollment. They will assess real world response rate, duration of response, time to treatment discontinuation, and time to next treatment. Participants clinical progress and outcomes will be monitored through their usual healthcare visits, with no additional interventional procedures required for the study duration.

DESTINY-PANTUMOUR04